FDA issues complete response letter to Replimune’s RP1 for melanoma
Pharmaceutical Business Review
The decision affects Replimune's lead product candidate, which is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response.
pharminent
April 13, 2026 (Last updated: April 13, 2026)
Pharmaceutical Business Review
The decision affects Replimune’s lead product candidate, which is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response.